Golidocitinib
- Generic Name
- Golidocitinib
- Drug Type
- Small Molecule
- Chemical Formula
- C25H31N9O2
- CAS Number
- 2091134-68-6
- Unique Ingredient Identifier
- 3BY9Z3M34G
Golidocitinib in Combination With Sintilimab for PD-L1 Selected Treatment Locally Advanced or Metastatic Non-Small Cell Lung Cancer(NSCLC)
Phase 2
Not yet recruiting
- Conditions
- Non-Small-Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-01-10
- Last Posted Date
- 2024-01-10
- Target Recruit Count
- 69
- Registration Number
- NCT06198907
- Locations
- 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
Go-CHOP as the Frontline Therapy for PTCL
Phase 2
Recruiting
- Conditions
- Peripheral T Cell Lymphoma
- Interventions
- Drug: CHOP Regimen
- First Posted Date
- 2023-07-27
- Last Posted Date
- 2023-09-01
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 45
- Registration Number
- NCT05963347
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL (JACKPOT8)
Phase 1
Completed
- Conditions
- Relapsed or Refractory Peripheral T Cell Lymphoma
- Interventions
- First Posted Date
- 2019-09-26
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- Dizal Pharmaceuticals
- Target Recruit Count
- 171
- Registration Number
- NCT04105010
- Locations
- 🇺🇸
Winship Cancer Institute, Atlanta, Georgia, United States
🇦🇺St George Hospital, Kogarah, Australia
🇰🇷Inje University Busan Paik Hospital, Busan, Korea, Republic of
A Study of AZD4205 in Healthy Adult Subjects
- First Posted Date
- 2018-11-01
- Last Posted Date
- 2020-08-24
- Lead Sponsor
- Dizal Pharmaceuticals
- Target Recruit Count
- 66
- Registration Number
- NCT03728023
- Locations
- 🇺🇸
Frontage clinical service, Secaucus, New Jersey, United States
Assessing an Oral Janus Kinase Inhibitor, AZD4205, in Combination With Osimertinib in Patients Who Have Advanced Non-small Cell Lung Cancer
- First Posted Date
- 2018-03-01
- Last Posted Date
- 2020-08-24
- Lead Sponsor
- Dizal Pharmaceuticals
- Target Recruit Count
- 10
- Registration Number
- NCT03450330
- Locations
- 🇦🇺
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
🇦🇺Northern Cancer Institute St Leonards, Sydney, Australia
🇦🇺Austin Hospital, Heidelberg, Victoria, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath